SCHEMBL3832563

SCHEMBL3832563

O=C(O)N[C@H]1CCN(C(=O)c2sc3c(ccc(=O)n3-c3ccccc3)c2Nc2ccc(F)cc2F)C1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.37
LMNA P02545 2/20 0.37
RECQL P46063 1/20 0.37
GFER P55789 1/20 0.36
MEN1 O00255 2/20 0.35
GAA P10253 2/20 0.35
KMT2A Q03164 2/20 0.35
MTOR P42345 1/20 0.35
RPTOR Q8N122 1/20 0.35
MLST8 Q9BVC4 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
OPRM1 P35372 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
BTK Q06187 1/20 0.34
F10 P00742 2/20 0.33
KDM4E B2RXH2 1/20 0.33
MAPK1 P28482 1/20 0.33
HSD17B10 Q99714 1/20 0.33
SIGMAR1 Q99720 1/20 0.33
CCNA2 P20248 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3831256 1.00 ALDH1A1 (0.37) ALDH1A1LMNARECQLGFERMEN1
SCHEMBL3836653 0.95 ALDH1A1 (0.40) ALDH1A1LMNARECQLMEN1GAA
SCHEMBL3830953 0.94 ALDH1A1 (0.37) ALDH1A1LMNARECQLGFERMEN1
SCHEMBL1266914 0.90 CXCR1 (0.39) ALDH1A1LMNARECQLMEN1GAA
SCHEMBL1266312 0.90 CXCR1 (0.39) ALDH1A1LMNARECQLMEN1GAA
SCHEMBL1265490 0.89 ALDH1A1 (0.38) ALDH1A1LMNARECQLMEN1GAA
SCHEMBL1266253 0.89 ALDH1A1 (0.38) ALDH1A1LMNARECQLMEN1GAA
SCHEMBL1266542 0.89 ALDH1A1 (0.38) ALDH1A1LMNARECQLMEN1GAA
SCHEMBL1266526 0.88 ALDH1A1 (0.41) ALDH1A1LMNARECQLKMT2ASMN1; SMN2
SCHEMBL1266862 0.87 ALDH1A1 (0.41) ALDH1A1LMNARECQLKMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7521460-B2 Thienopyridone derivatives as kinase inhibitors UCB PHARMA S.A. (BE) 2009-04-21 US disclosed
US-20070099894-A1 e.g. 3-[(2,4-Difluorophenyl)amino]-2-{[(2R)-2-(hydroxymethyl)pyrrolidin-1-yl]carbonyl}-7-phenylthieno[2,3-b]pyridin-6(7H)-one; autoimmune, neurodegenerative disorders, antiinflammatory agent; p38 MAP kinase inhibitor CELLTECH R&D LIMITED (GB) 2007-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070099894-A1 e.g. 3-[(2,4-Difluorophenyl)amino]-2-{[(2R)-2-(hydroxymethyl)pyrrolidin-1-yl]carbonyl}-7-phenylthieno[2,3-b]pyridin-6(7H)-one; autoimmune, neurodegenerative disorders, antiinflammatory agent; p38 MAP kinase inhibitor MAPK1, MAPKAPK2, MAPK6 ALDH1A1 2989/4885LMNA 3606/4885RECQL 3129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.